AMF. Promis Neurosciences

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, interim Chief Executive Officer of ProMIS Neurosciences and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 6, 2024 at 12:00 p.m. ET.

A live webcast of the fireside chat will be available to conference participants.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts.

For further information:

Visit us at

Please submit media inquiries to .

For Investor Relations, please contact:

Precision AQ

Anne Marie Fields, Managing Director



Tel. 212-362-1200



EN
01/08/2024

Underlying

AMF.Promis Neurosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Promis Neurosciences

 PRESS RELEASE
Free
AMF. Promis Neurosci...

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial...

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease   Six-month Interim Results Expected in 1H 2026 with Topline Results Anticipated in 2H 2026 CAMBRIDGE, Massachusetts, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodege...

February 25, 2025 1 EN
 PRESS RELEASE
Free
AMF. Promis Neurosci...

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap ...

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the Gug...

January 29, 2025 1 EN
 PRESS RELEASE
Free
AMF. Promis Neurosci...

ProMIS Neurosciences Issues Letter to Shareholders

ProMIS Neurosciences Issues Letter to Shareholders CAMBRIDGE, Massachusetts, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that its Chief Executive Officer, Neil Warma, issued the following letter to the Company’s shareholders. Dear ProMIS Shareholders, ...

January 13, 2025 1 EN
 PRESS RELEASE
Free
AMF. Promis Neurosci...

ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in...

ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients CAMBRIDGE, Massachusetts, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b clinical trial (PRECISE-AD) evaluating its lead therapeutic candidate, PMN310, in Alzheimer’s dis...

January 10, 2025 1 EN
 PRESS RELEASE
Free
AMF. Promis Neurosci...

ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx ...

ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside cha...

November 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch